CDK19 and prostate cancer: Elevated mediator complex sub-type CDK19 expression associated with aggressiveness of prostate cancer [32]; Pan-Cancer Analysis of the Mediator Complex Transcriptome determined CDK19 and CDK8 as treatment targets in late-period prostate carcinoma [33].